InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
renaissance1 Free
03/11/24 9:46 PM
profile icon
drkazmd65 Free
03/06/24 3:56 PM
Bullish
Bullish
profile icon
fung_derf Grandfathered
03/06/24 10:54 AM
profile icon
drkazmd65 Free
03/06/24 10:24 AM
profile icon
rdneum Free
03/06/24 9:24 AM
profile icon
drkazmd65 Free
02/22/24 8:42 AM
profile icon
G8TSTFL Free
02/18/24 8:44 AM
profile icon
fung_derf Grandfathered
02/13/24 5:52 PM
profile icon
bluepelican Free
02/13/24 5:27 PM
profile icon
hogg Free
02/09/24 2:56 PM
profile icon
fung_derf Grandfathered
02/09/24 12:57 PM
profile icon
exwannabe Free
02/09/24 12:57 PM
profile icon
hogg Free
02/09/24 12:48 PM
profile icon
tigerpac Free
02/09/24 11:25 AM
profile icon
steve2150 Free
02/09/24 10:48 AM
profile icon
Foxwoods Man Free
02/09/24 10:46 AM
profile icon
fung_derf Grandfathered
02/09/24 10:02 AM
profile icon
BigHeis Free
02/09/24 9:24 AM
profile icon
drkazmd65 Free
02/09/24 9:21 AM
profile icon
RobotDroid Free
02/09/24 9:12 AM
profile icon
BigHeis Free
02/09/24 9:10 AM
profile icon
drkazmd65 Free
02/06/24 9:33 AM
profile icon
fung_derf Grandfathered
01/31/24 10:42 AM
profile icon
BigHeis Free
01/31/24 9:56 AM
profile icon
fung_derf Grandfathered
01/29/24 10:56 AM
profile icon
renaissance1 Free
01/26/24 6:50 PM
profile icon
renaissance1 Free
01/26/24 12:08 PM
profile icon
drkazmd65 Free
01/25/24 9:49 AM
profile icon
fung_derf Grandfathered
01/22/24 2:03 PM
profile icon
PARker1703 Free
01/22/24 1:20 PM
profile icon
Tonymd Free
01/08/24 9:10 PM
profile icon
fung_derf Grandfathered
01/08/24 1:42 PM
profile icon
The_Q Free
01/06/24 4:07 PM
profile icon
conix Free
01/01/24 10:04 AM
profile icon
drkazmd65 Free
12/27/23 3:43 PM
profile icon
renaissance1 Free
12/26/23 10:51 PM
profile icon
Foxwoods Man Free
12/26/23 3:16 PM
profile icon
drkazmd65 Free
12/26/23 2:22 PM
profile icon
renaissance1 Free
12/26/23 1:22 PM
profile icon
drkazmd65 Free
12/26/23 12:24 PM
profile icon
conix Free
12/24/23 2:17 PM
profile icon
Tonymd Free
12/21/23 9:09 AM
profile icon
BigHeis Free
12/18/23 9:51 AM
profile icon
conix Free
12/17/23 8:35 PM

Cel Sci Corporation (CVM) RSS Feed

Followers
381
Posters
941
Posts (Today)
0
Posts (Total)
43697
Created
06/10/00
Type
Free
Moderators drkazmd65

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4





Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

    Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1


https://frugalnorwegian.com/cvm  Insight into CVM P3 Trial Results

https://www.cvmresearch.com  Insight into CVM P3 Trial Results & FDA Chances of Approval

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post